Clinical trial NCT00441818: Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Official title: A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Hodgkin's Lymphoma
Lead sponsor: Tanox
Sponsor class: INDUSTRY
First posted: 2007-03-01
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.

Detailed description: Hodgkin's lymphoma (HL) is a lymphoid malignancy that accounts for approximately 7,000 to 8,000 new cancer cases per year in the United Sates. It occurs with a bimodal age-incidence distribution peaking in the 15- to 30-year old and 50- to 60-year old age groups. The pathological hallmark of the disease is the presence of malignant Reed Sternberg (RS) cells. Reed-Sternberg cells are interspersed among a heterogeneous population of non-malignant reactive cells, including T cells, eosinophils, neutrophils, B lymphocytes, plasma cells, histiocytes, fibroblasts, and stromal cells.

While more than 80% of patients will respond to initial radiotherapy or combination chemoradiotherapy, some patients will experience early relapse after initial therapy or be refractory to first-line therapy. These patients may be treated with second-line therapy, which may include autologous bone marrow transplantation (BMT). Patients with HL who relapse after first- and second-line therapy, or who are refractory to therapy, with or without autologous BMT, have a poor prognosis. The long-term event-free survival rate in this patient group is less than 10%; median survival is 16 months. At present, these patients have no treatment options other than investigational therapies.

Eligibility criteria: Inclusion Criteria:

* Histological diagnosis of relapsed or refractory classical HL
* Age \>18 years
* Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP)
* Relapsed following autologous bone marrow transplantation (BMT), or are ineligible, or refused BMT
* Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry
* Completed autologous BMT (if received) at least 3 months prior to study entry; completed allogeneic BMT (if received); at least 6 months prior to study entry
* Eastern Cooperative Oncology Group (ECOG) status of \<2
* Life expectancy of \>3 months
* Laboratory data:

  * Platelet count \>50,000/mm3
  * Hemoglobin \>9.0 g/dL (may be maintained by transfusion)
  * Absolute neutrophil count \>1000/mm3
  * ALT/AST \<2.5 times the upper limit of normal (ULN)
  * Total bilirubin \<1.5 times ULN
  * Creatinine \<1.5 mg/dL
* Female subjects of childbearing potential must have a negative serum pregnancy test at screening; subjects must agree to use a medically appropriate form of birth control from screening until 6 months after the last dose of study medication
* Ability to provide written informed consent

Exclusion Criteria:

* Any significant diseases (other than HL) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the subject from participating in the study
* History or clinical evidence of cnetral nervous system (CNS) HL
* Received allogeneic BMT
* Received growth factor support or transfusions to achieve hematology entry criteria (platelets, hemoglobin, absolute neutrophil count)
* Major surgery within 4 weeks prior to study entry
* Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation
* Known history of another primary malignancy that has not been in remission for at least 5 years. Non-melanoma skin cancer and cervical carcinoma in situ or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia \[CIN\] or prostatic intraepithelial/intraductal neoplasia \[PIN\]) are allowed.
* Any active viral, bacterial, or systemic fungal infection within 4 weeks prior study entry
* Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)
* Histry of significant chronic or recurrent infections requiring treatment
* Receiving systemic steroids exceeding 10 mg prednisone or equivalent, or unstable on steroid medication, during the 3 weeks immediately preceding enrollment
* Pregnant or breast-feeding

Primary outcomes:
measure: To determine the safety and tolerability of TNX-650 for Injection when administered to patients with refractory Hodgkin's Lymphoma (HL)
measure: To determine the maximum tolerated dose (MTD) of TNX-650 for Injection
measure: To determine the systemic exposure to TNX-650 for Injection in patients with refractory HL
measure: To determine phosphorylated STAT-6 and IL-13Rα1 levels in tumor samples, and serum IL 13 levels, which may be useful as early prognostic indicators of efficacy in later clinical studies
measure: To determine the preliminary efficacy of TNX-650 for Injection at the maximum tolerated dose (MTD) or pharmacologically active dose, if MTD is not reached, based on tumor assessments using computed tomography (CT) or magnetic resonance imaging (MRI), and
Secondary outcomes:
measure: To determine the safety profile of TNX-650 for Injection at the MTD
measure: To determine phosphorylated STAT-6 and IL-13Rα1 levels in tumor samples, and serum IL 13 levels, which may be useful as early prognostic indicators of efficacy in later clinical studies
measure: To determine the preliminary efficacy of TNX-650 for Injection at the MTD, based on tumor assessments using CT or MRI, and FDG-PET
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Houston
country: United States
facility: MD Anderson Cancer Center - Dept. of Lymphoma and Myeloma
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Anas Younes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Memorial Sloan Kettering Cancer Center
name: Craig Moskowitz, MD
role: PRINCIPAL_INVESTIGATOR
References: